REALATED ARTICLES

Click on a word or phrase in our Tag Cloud and see all related articles listed below.

 

Current tag:

STEMCELL Technologies: Licensing Agreement Virus-Free Technology for Reprogramming Cells

June 14, 2010. STEMCELL Technologies Inc announced today that they have signed a licensing agreement with Stanford University for a virus-free technique used for the generation of induced pluripotent stem cells.   This technology will soon be commercially released by STEMCELL Technologies as STEMcircles™.

STEMcircles™ is a new and simple technology, published in Nature Methods (Jia F et al, 2010) that involves introducing reprogramming factors to cells using tiny circles of DNA.  Unlike other techniques, this method, which is based on standard molecular biology practices, does not use viruses to introduce genes into the cells.  Instead these DNA minicircles do not integrate into the genome and are naturally lost as the cells divide, overcoming some the safety concerns associated with current reprogramming methods. 

“The addition of non-viral, non-integrating STEMcircle™ reprogramming vectors  to our current product offering is an exciting new opportunity for STEMCELL Technologies as a leading provider of standardized, innovative and high quality tools for pluripotent stem cells”, commented Dr. Clive Glover, Product Management Manager at STEMCELL Technologies.

The STEMcircles™ technology works so well because the vector contains the minimal DNA sequences necessary for reprogramming.   Unlike the larger, more commonly used DNA plasmids, the minicircles contain no bacterial plasmid backbone DNA and as such are able to evade silencing mechanisms that cells naturally use against foreign DNA.  The result is more robust gene expression, and superior reprogramming over that of regular DNA plasmids.

Source: STEMCELL Technologies

____________________

Disclaimer: You agree that B2Bioworld is not responsible and will not be held liable for any third party content on its sites or any third-party content, products or services available on other web sites accessed through links from B2Bioworld sites. Links to third-party sites are for your convenience only, and their inclusion on B2Bioworld's sites does not imply any endorsement, guarantee, warranty or representation by B2Bioworld.

Related Articles

Stem Cell Insights Collection 2010

Issues and Evaluation from Pharma Leaders

Bayer AG: New Stakes in Stem Cells

Prof. Andreas Busch, Member of the Bayer HealthCare Executive Committee, responsible for Global Drug Discovery

Triggering Regenerative Functions with Transplanted Cells and Small Molecules

Prof. Kurt Stoeckli, Global Head of Biological Sciences / Discovery Sanofi Aventis and Scientific Director of the research site at Vitry-Alfortville

Doing our business a little bit differently than the others in industry

Dr. Mads Krogsgaard Thomsen, Executive Vice President and Chief Science Officer of Novo Nordisk

Pfizer Regenerative Medicine: “It really started last year…”

Dr Ruth McKernan, global CSO Pfizer Regenerative Medicine

Top 10 Tags

All Tags (2094)